In the automated cell cultures market, advancements have revolutionized biotechnology, offering numerous benefits. Automated systems streamline cell culture processes, enhancing efficiency and scalability while minimizing human error. These innovations enable real-time monitoring and precise control of culture conditions, optimizing cell growth and productivity. Additionally, automation accelerates research and drug development, reducing time and costs. Benefits extend to pharmaceuticals, biopharmaceuticals, and regenerative medicine industries, where reliable, high-throughput cell culture systems are crucial. The automated cell cultures market continues to thrive as technological advancements drive further improvements, fostering innovation and breakthroughs in various fields of science and medicine.
Data Bridge Market Research analyses that the Global Automated Cell Cultures Market size was valued at Euro 19,891.20 million by 2029, at a CAGR of 8.9% during the forecast period 2022 to 2029.
Below are the Top Five Automated Cell Cultures Companies with a Significant Market Share:
Rank
|
Company
|
Overview
|
Product/Service Portfolio
|
Sales Geographical Coverage
|
Developments
|
1.
|
Lonza
|
Lonza is a Swiss multinational company specializing in life sciences and biotechnology. Lonza offers a comprehensive range of products and services in the automated cell cultures market, including bioprocessing solutions and cell therapy technologies. Lonza's automated systems facilitate efficient cell culture workflows, ensuring reproducibility and scalability for various drug discovery, biomanufacturing, and regenerative medicine applications.
|
|
North and Central America, Africa, Europe, Latin America, Asia
|
In August, Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, announced that it would invest in establishing drug product manufacturing capabilities at its site in Guangzhou, China. The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services.
|
2.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific is a global leader in serving science, providing a broad range of innovative products and services. Thermo Fisher offers advanced bioproduction solutions in the automated cell cultures market, including automated cell culture systems and bioreactors. These systems enable precise control over cell culture parameters, enhancing productivity and ensuring consistent results across research and bioprocessing applications.
|
|
America, Middle East and Africa, Europe, Asia-Pacific
|
In April, Thermo Fisher Scientific Inc entered into a definitive agreement with PPD, Inc. According to the agreement, the company will acquire PPD, Inc. for USD 47.50/share of a total worth of USD 17.4 Billion. The agreement will help the company to develop new competencies and resources.
|
3.
|
Eppendorf
|
Eppendorf is a German company renowned for its high-quality laboratory equipment and consumables. Eppendorf offers innovative solutions such as automated cell culture systems and bioreactors in the automated cell cultures market. These systems integrate advanced technologies for cell cultivation, monitoring, and analysis, enabling researchers to streamline workflows and optimize cell culture processes for increased efficiency and reproducibility.
|
|
Europe, Africa, America, Asia-Pacific, China
|
In June, Eppendorf AG announced that it had launched epServices to calibrate pipettes, check the security of centrifuges, or verify the temperatures of PCR cycler. To make it even easier to get an overview of all offered services, users can now find the whole epServices portfolio in the Eppendorf app. It helps users discover all about the products and services bundled in one app on a mobile device.
|
4.
|
BD
|
BD (Becton, Dickinson, and Company) is a leading global medical technology company focused on improving healthcare delivery. BD provides advanced cell culture automation solutions in the automated cell cultures market, including automated cell culture systems and bioreactors. These technologies enable precise control over cell culture conditions, facilitating research, drug discovery, and bioproduction processes with enhanced efficiency and scalability.
|
|
Europe, Middle East and Africa, America, and Asia-Pacific
|
In June, BD participated in the International Society for the Advancement of Cytometry. This has helped the company to discuss the advancements in the fields of immunology and immune-oncology.
|
5.
|
Merck KGaA
|
Merck KGaA, headquartered in Germany, is a leading science and technology company in the healthcare, life sciences, and performance materials sectors. Merck offers a comprehensive portfolio of products and services in the automated cell cultures market, including automated cell culture systems, media, and reagents. These solutions empower researchers and bioprocess engineers to optimize cell culture processes, driving innovation and accelerating the development of novel therapies and biologics.
|
|
America, Middle East and Africa, Europe, Asia-Pacific
|
In August, Merck KGaA entered into a definitive agreement with Berlin-based Biochrom AG. According to the agreement, Merck KGaA has acquired Biochrom AG. The agreement has helped the company expand its cell portfolio and strengthen its Merck Millipore's Process Solutions business unit.
|
Conclusion
In conclusion, the automated cell cultures market presents a promising landscape driven by technological advancements and the growing demand for efficient cell culture processes. With automation integration, opportunities for enhanced reproducibility, scalability, and cost-effectiveness abound. As the life sciences industry evolves, embracing automated solutions offers a pathway to expedited research outcomes and therapeutic advancements, ultimately reshaping the landscape of biomedical research and biopharmaceutical production.